Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic symptoms in all...
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Antipsychotic Drugs: Therapeutic Uses and Side Effects01:21

Antipsychotic Drugs: Therapeutic Uses and Side Effects

Antipsychotic drugs primarily block dopamine and serotonin receptors and cholinergic, adrenergic, and histaminergic receptors, thereby reducing hallucinations and delusions in conditions like schizophrenia. However, they can trigger unwanted extrapyramidal effects such as dystonias, Parkinson-like symptoms, and tardive dyskinesia.
Despite these side effects, antipsychotics are used therapeutically for various purposes, including managing schizophrenia, preventing nausea and vomiting, curbing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Private Equity-Acquired Residential Treatment Facilities vs Other For-Profit Facilities.

JAMA health forum·2026
Same author

Lifetime Real-World Evidence on Safety and Performance of the First Active Transcutaneous Bone Conduction Implant (BCI), the Bonebridge Covering Conductive to Mixed Hearing Loss (CMHL), and Single-Sided Deafness (SSD): Results From a Long-Term Retrospective Analysis.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2026
Same author

Lifetime Real-World Evidence on Safety and Performance of the Only Active Middle Ear Implant (AMEI) Covering Conductive to Sensorineural Hearing Loss: Results From a Long-Term Retrospective Analysis.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2025
Same author

The Bonebridge BCI 602 Safety and Performance 1 Year Post-Implantation in Adults and Children: A Multicentric Post-Market Study.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2025
Same author

A Prospective, Multicenter Clinical Investigation on the Safety and Performance of a New Active Transcutaneous Bone-Anchored Implant System.

Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology·2025
Same author

Multicenter study results of the med-el partial ossicular replacement prostheses.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·2025

Related Experiment Video

Updated: Jul 13, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Rethinking antipsychotic formulary policy.

R A Rosenheck1, D L Leslie, Susan Busch

  • 1Yale Medical School, New Haven, CT, USA. Robert.Rosenheck@Yale.Edu

Schizophrenia Bulletin
|July 20, 2007
PubMed
Summary

Second-generation antipsychotics (SGAs) may not be more effective than first-generation antipsychotics (FGAs) and carry higher risks and costs. A new algorithm for antipsychotic therapy is proposed to address these findings.

Related Experiment Videos

Last Updated: Jul 13, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

Area of Science:

  • Psychiatry
  • Pharmacology

Background:

  • Recent research questions the superior efficacy of second-generation antipsychotics (SGAs) compared to first-generation antipsychotics (FGAs).
  • The perceived lower risk of extrapyramidal symptoms (EPS) and tardive dyskinesia with SGAs is less supported by evidence than previously assumed.
  • SGAs may present greater metabolic risks and significantly higher costs, potentially outweighing their benefits.

Purpose of the Study:

  • To critically review current research on the comparative effectiveness and safety of SGAs versus FGAs.
  • To propose a revised algorithm for antipsychotic maintenance therapy based on updated evidence.
  • To suggest a framework for implementing treatment changes with standardized documentation and feedback.

Main Methods:

  • Literature review of recent research on antipsychotic efficacy and adverse effects.
  • Development of a novel algorithm for antipsychotic maintenance therapy.
  • Outline of a cautious implementation strategy for clinical practice.

Main Results:

  • Evidence suggests SGAs may not offer superior efficacy over FGAs.
  • The reduced risk profile for EPS and tardive dyskinesia with SGAs is weakly supported.
  • Metabolic side effects and higher costs associated with SGAs are significant concerns.

Conclusions:

  • A reassessment of antipsychotic treatment guidelines is warranted.
  • A new algorithm prioritizing cost-effectiveness and risk-benefit profiles is proposed.
  • Implementation should involve careful monitoring and physician autonomy, avoiding restrictive formularies.